Gilead Sciences, Inc. $GILD Shares Purchased by WINTON GROUP Ltd

Key Points

• WINTON GROUP Ltd boosted its position in Gilead by 47.3% in Q3, buying 21,427 shares to hold 66,742 shares worth about $7.41M, while institutional investors collectively own roughly 83.67% of the stock.
• Gilead beat quarterly expectations with $1.86 EPS (vs. $1.83 est.) and $7.93B revenue, and issued FY2026 guidance of 8.45–8.85 EPS (analysts currently ~7.95).
• The company raised its quarterly dividend to $0.82 per share (annualized $3.28, ~2.3% yield), with an ex-dividend date of March 13 and payment on March 30.

WINTON GROUP Ltd increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 47.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,742 shares of the biopharmaceutical company's stock after purchasing an additional 21,427 shares during the quarter. WINTON GROUP Ltd's holdings in Gilead Sciences were worth $7,408,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Csenge Advisory Group grew its stake in Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company's stock valued at $2,375,000 after acquiring an additional 16,288 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company's stock worth $8,713,000 after purchasing an additional 26,882 shares in the last quarter. Cookson Peirce & Co. Inc. boosted its holdings in shares of Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company's stock worth $1,115,000 after purchasing an additional 7,168 shares during the last quarter. Railway Pension Investments Ltd boosted its holdings in shares of Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company's stock worth $157,139,000 after purchasing an additional 42,200 shares during the last quarter. Finally, TriaGen Wealth Management LLC purchased a new stake in shares of Gilead Sciences in the third quarter valued at approximately $1,274,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

GILD stock opened at $144.08 on Monday. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The stock has a market cap of $178.86 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 1.89 and a beta of 0.36. The business has a fifty day moving average of $138.29 and a two-hundred day moving average of $125.85.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company's quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Friday, March 13th. Gilead Sciences's dividend payout ratio (DPR) is 46.68%.

Analyst Ratings Changes

A number of brokerages recently commented on GILD. UBS Group lifted their price objective on Gilead Sciences from $145.00 to $155.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. Wall Street Zen cut Gilead Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, January 23rd. Needham & Company LLC reiterated a "buy" rating and set a $170.00 price target on shares of Gilead Sciences in a report on Monday, February 23rd. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the company an "overweight" rating in a research report on Wednesday, February 11th. Finally, Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a "buy" rating in a report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $156.72.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the sale, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 309,280 shares of company stock valued at $43,935,470 over the last 90 days. Insiders own 0.27% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.